Biomunex CEO on earlier deals for cancer drugs

During the recent BIO-Europe Spring partnering conference in Barcelona, Biomunex CEO Pierre-Emmanuel Gerard chats with Scrip about the company's strategy for partnering with pharmas in the cancer drug development space. He also comments on the recent trend of companies seeking earlier stage deals in cancer drug development and the benefits of this approach for both smaller biotechs and their larger pharma partners.

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Pierre-Emmanuel Gerard – CEO, Biomunex